drugset
drugset / Trial / NCT02677701

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701 ↗

Phase 4 Completed 119 enrolled Seattle Children's Hospital CF Therapeutics Development Network Coordinating Center · collabCystic Fibrosis Foundation · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to examine the effect of combining chronic oral azithromycin with inhaled tobramycin in adolescent and adult subjects with cystic fibrosis who are chronically infected with P. aeruginosa.

Timeline

Start
2016-10-21
Primary completion
2020-02-13
Completion
2020-02-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 500 mg Oral
Comparator Tobramycin Small molecule — Inhaled

Indications

cystic fibrosis